Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States.

ABSTRACT:

Introduction

Fecal microbiota spores, live-brpk (hereafter VOS) is a microbiota-based orally administered therapeutic approved by the United States Food and Drug Administration for prevention of recurrent Clostridioides difficile infection (rCDI) following standard-of-care (SoC) antibiotics for the treatment of rCDI in patients aged ≥ 18 years. The study objective was to estimate the budget impact of introducing VOS within a hypothetical United States (US) health plan.

Methods

A model was developed estimating the health plan budget impact of adding VOS to SoC compared with SoC alone for rCDI. Input data were from the published literature. Uptake of VOS was assumed at 10%, 20%, 30%, and 40% for recurrences 1 through 4, respectively. Annual and per-member per-month (PMPM) cost

SUBMITTER: Wilson M 

PROVIDER: S-EPMC12339835 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature